RT Journal Article
SR Electronic
T1 Effects of sub-anesthetic oro-mucosal dexmedetomidine on sleep in humans: A pharmacokinetics-pharmacodynamics study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.03.24309892
DO 10.1101/2024.07.03.24309892
A1 Schnider, Laura K.
A1 Ratajczak, Marta
A1 Wespi, Rafael
A1 Kientsch, Jacqueline G.
A1 Bavato, Francesco
A1 Marten, Laurenz
A1 Kost, Jonas
A1 Puchkov, Maxim
A1 Eicher, Corinne
A1 Boxier, Martina
A1 Voegel, Clarissa D.
A1 Bosch, Oliver G.
A1 van Someren, Eus
A1 Dornbierer, Dario A.
A1 Landolt, Hans-Peter
YR 2024
UL http://medrxiv.org/content/early/2024/08/22/2024.07.03.24309892.abstract
AB Background The locus coeruleus noradrenergic (LC-NE) system may provide a potential new target for pharmacological insomnia treatment, particularly in patients suffering from elevated stress. The selective α2 noradrenergic agonist dexmedetomidine (DEX) attenuates LC-NE activity in sub­ anesthetic doses, yet no adequate non-parental delivery systems of DEX are currently available. To examine the feasibility of oro-mucosal DEX administration, we developed two distinct – one sublingual and one buccal – oro-mucosal, fast-disintegrating DEX formulas tailored for self­ administration. Here we established their pharmacokinetic and pharmacodynamic (PK-PD) profiles.Methods In two separate studies in 8 male good sleepers and 17 men with subclinical insomnia, we administered sub-anesthetic doses (20 & 40 µg) of the two formulas following a randomized, double-blind, placebo-controlled, cross-over design. We complemented the PK assessments with all­ night polysomnography, nocturnal cortisol and melatonin measurements, assessments of cardiovascular functions during and after sleep, cortisol awakening response, and post-awakening examination of subjective state and vigilance.Results Particularly buccal DEX was rapidly absorbed and exhibited excellent dose-proportionality with minimal between-subject variation in exposure. In poor sleepers, 40 µg of buccal DEX shortened the sleep latency by 11 min, increased the time spent in non-rapid-eye-movement sleep by 38 min, and elevated electroencephalographic slow wave energy (0.75-4.0 Hz) in the first half of the night by 23 % (Pall < 0.05). Rapid-eye-movement sleep latency was dose-dependently prolonged (20 µg: 48 min; 40 µg: 117 min; Pall < 0.01). Nocturnal cortisol, melatonin and heart rate, and morning cortisol were not significantly affected by DEX, nor did post-awakening orthostatic regulation, subjective sleepiness and mood, and psychomotor vigilance differ among the conditions.Conclusions The favorable PK-PD profile of oro-mucosal DEX delivery warrants further dose-finding and clinical studies, to establish the exact roles of α2 receptor agonism in pharmacological sleep enhancement and as possible novel mechanism to alleviate stress-related insomnia.Competing Interest StatementRafael Wespi, MSc, Dario A. Dornbierer, PhD, and Hans-Peter Landolt, PhD are listed as inventors on a pending patent on "Dexmedetomidine for the treatment of sleep disorders" (UniTectra Fall-Nr. UZ 231534a) that is assigned to University of Zurich, Zurich, Switzerland. Further, Dario A. Dornbierer, PhD, declares that he co-founded Reconnect Labs, an academic spin-off company of the University of Zurich, focused on the development of dexmedetomidine-based products for the treatment of sleep disorders.Clinical TrialClinicalTrials.gov: Identifier # NCT04508166Funding StatementThis work was supported by InnoSuisse (grant # 55588.1 INNO-LS), the European Research Council (AdG grant # 101055383), the Wellcome Trust (grant # 227100/Z/23/Z), as well as Institutional funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study procedures were reviewed and approved by the Cantonal Ethics Committee of the Canton of Zurich (BASEC # 2020-016114). All participants provided written informed consent according to the declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available after peer-reviewed publication upon reasonable request to the authors.